Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Single-center, Randomized, Double-blind, Placebo-controlled, Sequential Cohort Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAD of FXI-GalNAc-siRNA When Administered Subcutaneously to Healthy Subjects.

Next Previous
X
Search
Trial Profile

Single-center, Randomized, Double-blind, Placebo-controlled, Sequential Cohort Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAD of FXI-GalNAc-siRNA When Administered Subcutaneously to Healthy Subjects.

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Jul 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs STP-122G (Primary)
  • Indications Atrial fibrillation; Deep vein thrombosis; Pulmonary embolism; Thrombosis
  • Focus Pharmacokinetics
  • Sponsors Sirnaomics

    • Most Recent Events

    • 08 Jul 2024 Interim Results published in the Sirnaomics Ltd. Media Release.
    • 05 Dec 2023 According to a Sirnaomics media release, the cohort 1 of study has been completed, Cohort 1 comprised of eight subjects who completed dosing and were followed over a period of 140 days. Safety data showed there were no dose-limiting toxicities or serious adverse events, so the study will proceed to the next dosing cohort. The company plans to enroll up to five escalating dosing cohorts.
    • 01 Jun 2023 According to a Sirnaomics media release, the first participant has been dosed in this study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top